<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1717">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04341103</url>
  </required_header>
  <id_info>
    <org_study_id>Al-COVE</org_study_id>
    <nct_id>NCT04341103</nct_id>
  </id_info>
  <brief_title>AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience</brief_title>
  <acronym>Al-COVE</acronym>
  <official_title>AlloSure Guided Immuno-Optimization for COVID-19: An Early Experience</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CareDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CareDx</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The utilization of AlloSure to help guide immunosuppression management in solid organ
      transplant recipients diagnosed with COVID-19
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An observational case series of patients with solid organ transplants who have been admitted
      with suspected COVID-19 utilizing AlloSure dd-cf DNA to help guide immunosuppression
      management balancing the treatment of sepsis and avoiding allograft rejection.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing the utility of AlloSure dd-cfDNA to guide clinical immune-optimization for transplant patients with COVID-19</measure>
    <time_frame>6 months</time_frame>
    <description>AlloSure dd-cfDNA blood draw values</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Solid Organ Transplant Rejection</condition>
  <condition>COVID-19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Solid organ (liver, heart, lung or kidney) transplant recipients diagnosed with suspected
        or confirmed case of COVID-19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver, Heart, Lung or Kidney organ transplant recipient with a suspected or confirmed
             diagnosis of COVID-19

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alana Burns</last_name>
    <phone>415.287.2420</phone>
    <email>aburns@caredx.com</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2020</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

